Q1 FY27 Results: Revenue up 30% YoY, PAT more than doubles

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.7%Reaction day

₹1682.20

prior close

₹1621.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+5.4% vs market

Pharmaceuticals peers, median of 165sector+0.1%+5.6% vs sector

On the reaction day the stock moved 5.4 pts more than Nifty Microcap 250 and 5.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+7.5

10m

+9.7

15m

+9.7

30m

+9.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.7+0.3+5.4+0.1+5.6

Next day

+0.3-0.9+1.1-1.5+1.8

-1.9-1.5-0.4-2.1+0.2

-2.1-1.1-1.0-2.3+0.2

-6.5+0.2-6.7-1.5-5.0

-8.8-1.1-7.7-2.2-6.5

-8.5-1.2-7.3-2.6-5.9

15d

-6.1+3.1-9.3+0.3-6.5

+3.8+4.5-0.6-0.7+4.6

-5.6+4.5-10.1+1.3-6.9

-10.0-2.2-7.7-5.8-4.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies Q1FY27 standalone revenue grew 30% YoY to Rs 178.80 Cr from Rs 137.13 Cr. Net profit more than doubled to Rs 25.53 Cr from Rs 11.70 Cr. EBITDA rose to Rs 39.11 Cr from Rs 20.66 Cr. Consolidated PAT reached Rs 22.97 Cr vs Rs 9.60 Cr. Auditor flagged emphasis of matter on Rs 28.60 Cr pending share application money in German subsidiary Venus Pharma GmbH facing financial challenges. Board also approved MOA revisions to align with Companies Act 2013, expanding scope to include biotech, digital and telehealth businesses, pending shareholder approval.

Likely market impact

Strong Q1 with over 30% revenue growth and more than doubled profit. Watch German subsidiary exposure needing ongoing support.